Articles From: PetSmart, Inc. Acquisition By BC Partners, Inc. Is The Subject Of A Legal Investigation to Pfizer Declares First-Quarter 2015 Dividend


2014/12/15
NEW YORK , Dec.
Sign-up for PetSmart, Inc. Acquisition By BC Partners, Inc. Is The Subject Of A Legal Investigation investment picks
2014/12/15
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of PetSmart, Inc. (“PetSmart”) (NasdaqGS: PETM) concerning the sale to BC Partners, Inc. Under the terms of the agreement, PetSmart shareholders will only receive $83.00 in cash for each share owned, which is less than a 7% premium over the closing price just before the deal was announced and virtually no premium over 52-week high.
Sign-up for PETSMART, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to BC Partners, Inc. investment picks
2014/12/31
Rigrodsky & Long, P.A.: Do you own shares of PetSmart, Inc. (NASDAQ GS: PETM )? Did you purchase any of your shares prior to December 15, 2014?
Sign-up for PETSMART, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout investment picks
2014/12/15
WILMINGTON, Del.
Sign-up for PETSMART, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout investment picks
2014/12/16
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1165223&ProfileId=051205&sourceType=1 SANTA CLARA, CA --
Sign-up for Petzila Selects Marvell's EZ-Connect(TM) to Power Their Latest Pet Technology, PetziConnect investment picks
2015/2/18
By Jason Chow PARIS--French car maker PSA Peugeot Citroën announced a smaller loss in 2014 as strong sales in China and cost-cutting efforts improved the company's results, though it warned that its Latin American and Russian operations would continue to struggle in the year ahead.
Sign-up for Peugeot Narrows Loss as Chinese Sales Sales Leap investment picks
2015/1/15
http://www.ccnmatthews.com/logos/20111129-peyto_200.jpg CALGARY, ALBERTA --
Sign-up for Peyto Exploration & Development Corp. Announces Management Team Additions and Confirms Dividends for First Quarter 2015 investment picks
2014/12/15
http://www.ccnmatthews.com/logos/20111129-peyto_200.jpg CALGARY, ALBERTA --
Sign-up for Peyto Exploration & Development Corp. Confirms Dividends for January 15, 2015 investment picks
2015/2/13
http://www.ccnmatthews.com/logos/20111129-peyto_200.jpg CALGARY, ALBERTA --
Sign-up for Peyto Exploration & Development Corp. Confirms Dividends for March 13, 2015 investment picks
2015/2/18
http://www.ccnmatthews.com/logos/20111129-peyto_200.jpg CALGARY, ALBERTA --
Sign-up for Peyto's 2014 Exit Production and Total Reserves Exceed 85,000 boe/d and 530 MMBOE investment picks
2015/2/2
http://www.ccnmatthews.com/logos/20081029-pfb1.jpg CALGARY, ALBERTA --
Sign-up for PFB Corporation Announces Regular Quarterly Dividend investment picks
2015/2/10
SAN DIEGO and LAKE FOREST, Ill.
Sign-up for Pfenex And Hospira Announce Collaboration To Develop And Commercialize Proposed LUCENTIS® Biosimilar investment picks
2014/12/22
SAN DIEGO , Dec.
Sign-up for Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L investment picks
2015/2/10
By Tess Stynes By Tess Stynes Pfenex Inc. said an exclusive collaboration deal with Hospira Inc. on the biosimilar drug developer's experimental generic biologic version of Genentech's Lucentis eye treatment, potentially valued at $342 million.
Sign-up for Pfenex shares rise on collaboration deal with Hospira investment picks
2015/2/27
SAN DIEGO , Feb.
Sign-up for Pfenex to Present at CALBIO 2015 investment picks
2015/1/29
SAN DIEGO , Jan.
Sign-up for Pfenex to Present at the 17th Annual BIO CEO and Investor Conference investment picks
2015/3/2
SAN DIEGO , March 2, 2015 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, today announced that it will be presenting at the 2015 Barclays Global Healthcare Conference in Miami, FL at the Loews Miami Beach Hotel.
Sign-up for Pfenex to Present at the 2015 Barclays Global Healthcare Conference investment picks
2015/2/13
SAN DIEGO , Feb.
Sign-up for Pfenex to Present at the 2015 RBC Capital Markets' Healthcare Conference investment picks
2015/1/5
By Angela Chen Pfizer Inc. has acquired a controlling interest in privately held Redvax GmbH, a move that gives the increasingly vaccine-focused drug giant access to a potential vaccine against a herpes virus.
Sign-up for Pfizer acquires Redvax for its potential herpes vaccine investment picks
2015/1/5
Pfizer Inc. today announced that it has acquired a controlling interest in Redvax GmbH, a spin-off from Redbiotec AG, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren.
Sign-up for Pfizer Acquires Redvax GmbH investment picks
2014/12/10
Nearly one out of every two (45.25%) American women will be menopausal or approaching menopause next year.
Sign-up for Pfizer and Brenda Strong Encourage Women to Change the Conversation on Sexual Health Post-Menopause investment picks
2015/2/13
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride), extended-release capsules, an abuse-deterrent formulation (ADF) opioid for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Sign-up for Pfizer Announces FDA Acceptance for Review of a New Drug Application for ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) investment picks
2015/2/4
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for XELJANZ ® (tofacitinib citrate) 5 mg and 10 mg tablets, a Janus kinase (JAK) inhibitor, the first in a new class of oral medicines being investigated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.
Sign-up for Pfizer Announces FDA Acceptance For Review Of Supplemental New Drug Application For Oral XELJANZ® (tofacitinib citrate) For Adult Patients With Moderate To Severe Chronic Plaque Psoriasis investment picks
2014/12/15
Pfizer Inc. (NYSE:PFE) today announced the publication of the detailed results from PALOMA-1, a randomized Phase 2 study of palbociclib in combination with letrozole versus letrozole alone, in The Lancet Oncology .
Sign-up for Pfizer Announces Palbociclib PALOMA-1 Data Published in The Lancet Oncology investment picks
2015/2/24
Pfizer Inc. (NYSE:PFE) announced today positive top-line results of a Phase 2 study of TRUMENBA ® (Meningococcal Group B Vaccine) co-administered with FDA-approved, routine meningococcal (groups A, C, Y and W) (MCV4) and single-dose tetanus, diptheria and pertussis (Tdap) vaccines in more than 2,600 healthy individuals 10 through 12 years of age.
Sign-up for Pfizer Announces Positive Top-line Results Of A Phase 2 Study Of TRUMENBA® (Meningococcal Group B Vaccine) Co-Administered With Routine Meningococcal (A, C, Y, and W) And Tetanus, Diptheria And Pertussis (Tdap) Vaccines In Adolescents investment picks
2015/2/25
By Robb M.
Sign-up for Pfizer Australia Lipitor Case Dismissed investment picks
2015/2/9
Pfizer Inc. (NYSE:PFE) today announced that it has entered into an accelerated share repurchase agreement with Goldman, Sachs & Co.
Sign-up for Pfizer Commences $5 Billion Accelerated Share Repurchase investment picks
2015/1/26
Pfizer Inc. (NYSE:PFE) today announced new commitments aimed at ensuring the world’s most resource-limited countries have access to Prevenar 13* (pneumococcal polysaccharide conjugate vaccine (PCV), 13 – valent, absorbed) through Gavi, the Vaccine Alliance.
Sign-up for Pfizer Commits to Further Reduce Price for Prevenar 13 in the World’s Poorest Countries Through 2025 investment picks
2014/12/15
The board of directors of Pfizer Inc. today declared a 28-cent first-quarter 2015 dividend on the company’s common stock, payable March 3, 2015, to shareholders of record at the close of business on February 6, 2015.
Sign-up for Pfizer Declares First-Quarter 2015 Dividend investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: PetSmart, Inc. Acquisition By BC Partners, Inc. Is The Subject Of A Legal Investigation to Pfizer Declares First-Quarter 2015 Dividend
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent